Targeting Neuroprotection as an Alternative Approach to Preventing and Treating Neuropathic Pain

Cata, 2006, Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy, Minerva Anestesiol, 72, 151 Davies, 2006, The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes, Diabetes Care, 29, 1518, 10.2337/dc05-2228 Vincent, 2004, Oxidative stress in the pathogenesis of diabetic neuropathy, Endocr Rev, 25, 612, 10.1210/er.2003-0019 Leinninger, 2006, Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy, Nat Clin Pract Neurol, 2, 620, 10.1038/ncpneuro0320 Tomlinson, 2008, Glucose neurotoxicity, Nat Rev Neurosci, 9, 36, 10.1038/nrn2294 McArthur, 2005, Neurological complications of HIV infection, Lancet Neurol, 4, 543, 10.1016/S1474-4422(05)70165-4 Childs, 1999, Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy, Neurology, 52, 607, 10.1212/WNL.52.3.607 Tagliati, 1999, Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings, Arch Neurol, 56, 84, 10.1001/archneur.56.1.84 Schifitto, 2005, Markers of immune activation and viral load in HIV-associated sensory neuropathy, Neurology, 64, 842, 10.1212/01.WNL.0000152981.32057.BB Lichtenstein, 2005, Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort, Clin Infect Dis, 40, 148, 10.1086/426076 Ferrari, 2006, Human immunodeficiency virus-associated peripheral neuropathies, Mayo Clin Proc, 81, 213, 10.4065/81.2.213 Pardo, 2001, HIV neuropathy: insights in the pathology of HIV peripheral nerve disease, J Peripher Nerv Syst, 6, 21, 10.1046/j.1529-8027.2001.006001021.x Simpson, 2006, HIV neuropathy natural history cohort study: assessment measures and risk factors, Neurology, 66, 1679, 10.1212/01.wnl.0000218303.48113.5d Cherry, 2006, Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort, Neurology, 66, 867, 10.1212/01.wnl.0000203336.12114.09 Keswani, 2006, Establishment of a rodent model of HIV-associated sensory neuropathy, J Neurosci, 26, 10299, 10.1523/JNEUROSCI.3135-06.2006 Pettersen, 2006, Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity, Ann Neurol, 59, 816, 10.1002/ana.20816 Ellis, 2008, Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy, Ann Neurol, 64, 566, 10.1002/ana.21484 Cherry, 2003, Nucleoside analogues and neuropathy in the era of HAART, J Clin Virol, 26, 195, 10.1016/S1386-6532(02)00118-X Dalakas, 2001, Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC), Lab Invest, 81, 1537, 10.1038/labinvest.3780367 Keswani, 2003, FK506 is neuroprotective in a model of antiretroviral toxic neuropathy, Ann Neurol, 53, 57, 10.1002/ana.10401 Zhu, 2007, Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression, Brain, 130, 2011, 10.1093/brain/awm148 Robinson, 2007, Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures, J Neurovirol, 13, 160, 10.1080/13550280701200102 El Idrissi, 1999, Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism, J Neurosci, 19, 9459, 10.1523/JNEUROSCI.19-21-09459.1999 Markham, 2004, BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II, Eur J Neurosci, 20, 1189, 10.1111/j.1460-9568.2004.03578.x Wolf, 2008, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, Eur J Cancer, 44, 1507, 10.1016/j.ejca.2008.04.018 Wilkes, 2007, Peripheral neuropathy related to chemotherapy, Semin Oncol Nurs, 23, 162, 10.1016/j.soncn.2007.05.001 Hausheer, 2006, Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy, Semin Oncol, 33, 15, 10.1053/j.seminoncol.2005.12.010 Rao, 2007, Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3), Cancer, 110, 2110, 10.1002/cncr.23008 McDonald, 2005, Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity, Neurobiol Dis, 18, 305, 10.1016/j.nbd.2004.09.013 Scuteri, 2009, Role of MAPKs in platinum-induced neuronal apoptosis, Neurotoxicology, 30, 312, 10.1016/j.neuro.2009.01.003 James, 2008, Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants, Neurotoxicology, 29, 605, 10.1016/j.neuro.2008.04.008 Graham, 2004, Oxaliplatin, Nat Rev Drug Discov, 3, 11, 10.1038/nrd1287 Grolleau, 2001, A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels, J Neurophysiol, 85, 2293, 10.1152/jn.2001.85.5.2293 Adelsberger, 2000, The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons, Eur J Pharmacol, 406, 25, 10.1016/S0014-2999(00)00667-1 Gamelin, 2007, Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway, Clin Cancer Res, 13, 6359, 10.1158/1078-0432.CCR-07-0660 Quasthoff, 2002, Chemotherapy-induced peripheral neuropathy, J Neurol, 249, 9, 10.1007/PL00007853 Apfel, 1991, Nerve growth factor prevents toxic neuropathy in mice, Ann Neurol, 29, 87, 10.1002/ana.410290115 Cavaletti, 1997, Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat, Neurotoxicology, 18, 137 Cavaletti, 1995, Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol, Exp Neurol, 133, 64, 10.1006/exnr.1995.1008 Authier, 2000, Description of a short-term taxol-induced nociceptive neuropathy in rats, Brain Res, 887, 239, 10.1016/S0006-8993(00)02910-3 Polomano, 2001, A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel, Pain, 94, 293, 10.1016/S0304-3959(01)00363-3 Flatters, 2006, Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction, Pain, 122, 245, 10.1016/j.pain.2006.01.037 Siau, 2006, Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells, Exp Neurol, 201, 507, 10.1016/j.expneurol.2006.05.007 Thant, 1982, Possible enhancement of vincristine neuropathy by VP-16, Cancer, 49, 859, 10.1002/1097-0142(19820301)49:5<859::AID-CNCR2820490506>3.0.CO;2-9 Evtodienko, 1996, Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria, FEBS Lett, 393, 86, 10.1016/0014-5793(96)00875-7 André, 2000, Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells, Cancer Res, 60, 5349 Helgason, 2000, Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up, BMJ, 321, 794, 10.1136/bmj.321.7264.794 Kost, 1996, Postherpetic neuralgia: pathogenesis, treatment, and prevention, N Engl J Med, 335, 32, 10.1056/NEJM199607043350107 Rowbotham, 1989, Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature, Pain, 39, 129, 10.1016/0304-3959(89)90001-8 Fields, 1998, Postherpetic neuralgia: irritable nociceptors and deafferentation, Neurobiol Dis, 5, 209, 10.1006/nbdi.1998.0204 Backonja, 2008, NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study [Erratum in: Lancet Neurol 2009;8:31], Lancet Neurol, 7, 1106, 10.1016/S1474-4422(08)70228-X Christo, 2007, Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management, Drugs Aging, 24, 1, 10.2165/00002512-200724010-00001 Sampathkumar, 2009, Herpes zoster (shingles) and postherpetic neuralgia, Mayo Clin Proc, 84, 274, 10.4065/84.3.274 Osterberg, 2005, Central pain in multiple sclerosis: prevalence and clinical characteristics, Eur J Pain, 9, 531, 10.1016/j.ejpain.2004.11.005 Boivie, 1989, Central post-stroke pain: a study of the mechanisms through analyses of the sensory abnormalities, Pain, 37, 173, 10.1016/0304-3959(89)90128-0 Finnerup, 2004, Spinal cord injury pain: mechanisms and treatment, Eur J Neurol, 11, 73, 10.1046/j.1351-5101.2003.00725.x Bowsher, 1996, Central pain: clinical and physiological characteristics, J Neurol Neurosurg Psychiatry, 61, 62, 10.1136/jnnp.61.1.62 Österberg, 2009, Central pain in multiple sclerosis: sensory abnormalities, Eur J Pain Lubetzki, 2005, Promoting repair in multiple sclerosis: problems and prospects, Curr Opin Neurol, 18, 237, 10.1097/01.wco.0000169739.83793.e0 Lopez-Diego, 2008, Novel therapeutic strategies for multiple sclerosis: a multifaceted adversary, Nat Rev Drug Discov, 7, 909, 10.1038/nrd2358 Sah, 2003, Neurotrophic factors as novel therapeutics for neuropathic pain, Nat Rev Drug Discov, 2, 460, 10.1038/nrd1107 Wang, 2009, TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain, J Neurosci, 29, 5508, 10.1523/JNEUROSCI.4288-08.2009 Hefti, 2006, Novel class of pain drugs based on antagonism of NGF, Trends Pharmacol Sci, 27, 85, 10.1016/j.tips.2005.12.001 Gardell, 2003, Multiple actions of systemic artemin in experimental neuropathy, Nat Med, 9, 1383, 10.1038/nm944 Brenner, 2004, Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons, Eur J Neurosci, 20, 375, 10.1111/j.1460-9568.2004.03506.x Ma, 1995, Noxious stimuli induce an N-methyl-d-aspartate receptor-dependent hypersensitivity of the flexion withdrawal reflex to touch: implications for the treatment of mechanical allodynia, Pain, 61, 383, 10.1016/0304-3959(94)00195-K Caterina, 1997, The capsaicin receptor: a heat-activated ion channel in the pain pathway, Nature, 389, 816, 10.1038/39807 Szallasi, 1999, Vanilloid (capsaicin) receptors and mechanisms, Pharmacol Rev, 51, 159 Gavva, 2007, The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation, J Neurosci, 27, 3366, 10.1523/JNEUROSCI.4833-06.2007 Waxman, 1999, Sodium channels and pain, Proc Natl Acad Sci U S A, 96, 7635, 10.1073/pnas.96.14.7635 Gold, 2003, Redistribution of NaV1.8 in uninjured axons enables neuropathic pain, J Neurosci, 23, 158, 10.1523/JNEUROSCI.23-01-00158.2003 Fang, 2005, trkA is expressed in nociceptive neurons and influences electrophysiological properties via Nav1.8 expression in rapidly conducting nociceptors, J Neurosci, 25, 4868, 10.1523/JNEUROSCI.0249-05.2005 Cox, 2006, An SCN9A channelopathy causes congenital inability to experience pain, Nature, 444, 894, 10.1038/nature05413 Fertleman, 2006, SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes, Neuron, 52, 767, 10.1016/j.neuron.2006.10.006 Lai, 2002, Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8, Pain, 95, 143, 10.1016/S0304-3959(01)00391-8 Ekberg, 2006, μO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits, Proc Natl Acad Sci U S A, 103, 17030, 10.1073/pnas.0601819103 Nassar, 2004, Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain, Proc Natl Acad Sci U S A, 101, 12706, 10.1073/pnas.0404915101 Nassar, 2005, Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8, Mol Pain, 1, 24, 10.1186/1744-8069-1-24 Abrahamsen, 2008, The cell and molecular basis of mechanical, cold, and inflammatory pain, Science, 321, 702, 10.1126/science.1156916 Waxman, 2006, Axonal conduction and injury in multiple sclerosis: the role of sodium channels, Nat Rev Neurosci, 7, 932, 10.1038/nrn2023 Petronilli, 1994, The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols: increase of the gating potential by oxidants and its reversal by reducing agents, J Biol Chem, 269, 16638, 10.1016/S0021-9258(19)89437-1 McStay, 2002, Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore, Biochem J, 367, 541, 10.1042/bj20011672 Veenman, 2008, VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis, J Bioenerg Biomembr, 40, 199, 10.1007/s10863-008-9142-1 Leung, 2008, Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore, Biochim Biophys Acta, 1777, 946, 10.1016/j.bbabio.2008.03.009 Pastorino, 2008, Regulation of hexokinase binding to VDAC, J Bioenerg Biomembr, 40, 171, 10.1007/s10863-008-9148-8 Carré, 2002, Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel, J Biol Chem, 277, 33664, 10.1074/jbc.M203834200 Lowell, 2005, Mitochondrial dysfunction and type 2 diabetes, Science, 307, 384, 10.1126/science.1104343 Leinninger, 2006, Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1, Neurobiol Dis, 23, 11, 10.1016/j.nbd.2006.01.017 Siau, 2006, Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy, Anesth Analg, 102, 1485, 10.1213/01.ane.0000204318.35194.ed Shu, 1999, Neurotrophins and hyperalgesia, Proc Natl Acad Sci U S A, 96, 7693, 10.1073/pnas.96.14.7693 Ogun-Muyiwa, 1999, Glial cell line derived neurotrophic factor (GDNF) regulates VR1 and substance P in cultured sensory neurons, Neuroreport, 10, 2107, 10.1097/00001756-199907130-00021 Hudson, 2001, VR1 protein expression increases in undamaged DRG neurons after partial nerve injury, Eur J Neurosci, 13, 2105, 10.1046/j.0953-816x.2001.01591.x Zhang, 2004, Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury, Brain Res, 1009, 147, 10.1016/j.brainres.2004.02.057 Mansour, 2006, Protective role of carnitine ester against radiation-induced oxidative stress in rats, Pharmacol Res, 54, 165, 10.1016/j.phrs.2006.04.003 Ferraresi, 2006, Protective effect of acetyl-l-carnitine against oxidative stress induced by antiretroviral drugs, FEBS Lett, 580, 6612, 10.1016/j.febslet.2006.11.016 Manfridi, 1992, Culture of dorsal root ganglion neurons from aged rats: effects of acetyl-l-carnitine and NGF, Int J Dev Neurosci, 10, 321, 10.1016/0736-5748(92)90021-Q Liu, 2002, Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-l-carnitine and/or R-α-lipoic acid [Erratum in: Proc Natl Acad Sci U S A 2002;99:7184], Proc Natl Acad Sci U S A, 99, 1876, 10.1073/pnas.261709098 Picconi, 2006, Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine, Neuropharmacology, 50, 917, 10.1016/j.neuropharm.2006.01.002 Alves, 2009, Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain, Neuroscience, 158, 514, 10.1016/j.neuroscience.2008.10.041 Fernandez, 1989, Effects of l-carnitine, l-acetylcarnitine and gangliosides on the regeneration of the transected sciatic nerve in rats, Neurol Res, 11, 57, 10.1080/01616412.1989.11739863 Mamoulakis, 2004, Carnitine deficiency in children and adolescents with type 1 diabetes, J Diabetes Complications, 18, 271, 10.1016/S1056-8727(03)00091-6 Famularo, 1997, Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues, AIDS, 11, 185, 10.1097/00002030-199702000-00008 Ido, 1994, Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-l-carnitine, Diabetes, 43, 1469, 10.2337/diab.43.12.1469 Lowitt, 1995, Acetyl-l-carnitine corrects the altered peripheral nerve function of experimental diabetes, Metabolism, 44, 677, 10.1016/0026-0495(95)90128-0 Nakamura, 1998, Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats, J Pharmacol Exp Ther, 287, 897 Stevens, 1996, Acetyl-l-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat, Metabolism, 45, 865, 10.1016/S0026-0495(96)90161-4 Sima, 1996, Primary preventive and secondary interventionary effects of acetyl-l-carnitine on diabetic neuropathy in the bio-breeding Worcester rat, J Clin Invest, 97, 1900, 10.1172/JCI118621 Ohsawa, 2008, Preventive effect of acetyl-l-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice, Eur J Pharmacol, 588, 213, 10.1016/j.ejphar.2008.04.029 Pisano, 2003, Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine, Clin Cancer Res, 9, 5756 Ghirardi, 2005, Acetyl-l-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties, Anticancer Res, 25, 2681 Flatters, 2006, Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy, Neurosci Lett, 397, 219, 10.1016/j.neulet.2005.12.013 Xiao, 2008, Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine, Pain, 135, 262, 10.1016/j.pain.2007.06.001 Piovesan, 1994, Acetyl-l-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection, Brain Res, 633, 77, 10.1016/0006-8993(94)91524-5 Foreman, 1995, Effects of acetyl-l-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats, Prog Neuropsychopharmacol Biol Psychiatry, 19, 117, 10.1016/0278-5846(94)00109-U Barhwal, 2008, Hypoxia-induced deactivation of NGF-mediated ERK1/2 signaling in hippocampal cells: neuroprotection by acetyl-l-carnitine, J Neurosci Res, 86, 2705, 10.1002/jnr.21722 Di Cesare Mannelli, 2007, Protective effect of acetyl-l-carnitine on the apoptotic pathway of peripheral neuropathy, Eur J Neurosci, 26, 820, 10.1111/j.1460-9568.2007.05722.x Pettegrew, 2000, Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression, Mol Psychiatry, 5, 616, 10.1038/sj.mp.4000805 Jin, 2008, Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells, Exp Neurol, 210, 229, 10.1016/j.expneurol.2007.11.001 Chiechio, 2002, l-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors, Mol Pharmacol, 61, 989, 10.1124/mol.61.5.989 Chiechio, 2006, Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-κB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of l-acetylcarnitine, Mol Pain, 2, 20, 10.1186/1744-8069-2-20 Ghelardini, 2002, Acetyl-l-carnitine induces muscarinic antinociception in mice and rats, Neuropharmacology, 43, 1180, 10.1016/S0028-3908(02)00225-3 Di Cesare Mannelli, 2009, Neuroprotective effects of acetyl-l-carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor, J Neurosci Res, 87, 200, 10.1002/jnr.21815 Grandis, 1998, Tolerability and efficacy of l-acetylcarnitine in patients with peripheral neuropathies: a short-term, open multicentre study, Clin Drug Investig, 15, 73, 10.2165/00044011-199815020-00001 Evans, 2008, Role of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy, Ann Pharmacother, 42, 1686, 10.1345/aph.1L201 Sima, 2005, Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials, Diabetes Care, 28, 89, 10.2337/diacare.28.1.89 Bianchi, 2005, Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine, Eur J Cancer, 41, 1746, 10.1016/j.ejca.2005.04.028 Maestri, 2005, A pilot study on the effect of acetyl-l-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy, Tumori, 91, 135, 10.1177/030089160509100206 Hart, 2004, Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy, AIDS, 18, 1549, 10.1097/01.aids.0000131354.14408.fb Herzmann, 2005, Long-term effect of acetyl-l-carnitine for antiretroviral toxic neuropathy, HIV Clin Trials, 6, 344, 10.1310/CH1N-YBNU-G3CU-JBXR Valcour, 2009, Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection, HIV Med, 10, 103, 10.1111/j.1468-1293.2008.00658.x Bordet, 2007, Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis, J Pharmacol Exp Ther, 322, 709, 10.1124/jpet.107.123000 Rostovtseva, 2008, Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration, Proc Natl Acad Sci U S A, 105, 18746, 10.1073/pnas.0806303105 Bordet, 2008, Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy, J Pharmacol Exp Ther, 326, 623, 10.1124/jpet.108.139410 Pabbidi, 2008, Direct role of streptozotocin in inducing thermal hyperalgesia by enhanced expression of transient receptor potential vanilloid 1 in sensory neurons, Mol Pharmacol, 73, 995, 10.1124/mol.107.041707 Simiand, 1993, Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist, Fundam Clin Pharmacol, 7, 413 Labie, 1999, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, Br J Pharmacol, 127, 139, 10.1038/sj.bjp.0702545 Fournier, 1993, Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates, Neuroscience, 55, 629, 10.1016/0306-4522(93)90429-J Cassidy, 2006, J Clin Oncol, 24, 3507, 10.1200/jco.2006.24.18_suppl.3507 Susman, 2006, Xaliproden lessens oxaliplatin-mediated neuropathy, Lancet Oncol, 7, 288, 10.1016/S1470-2045(06)70639-8 Kakinoki, 2006, Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals, Diabetes, 55, 616, 10.2337/diabetes.55.03.06.db05-1091 Calcutt, 2006, Protection of sensory function in diabetic rats by Neotrofin, Eur J Pharmacol, 534, 187, 10.1016/j.ejphar.2006.01.047 Gavish, 1999, Enigma of the peripheral benzodiazepine receptor, Pharmacol Rev, 51, 629 Galiegue, 2003, The peripheral benzodiazepine receptor: a promising therapeutic drug target, Curr Med Chem, 10, 1563, 10.2174/0929867033457223 Veenman, 2007, Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response, Curr Pharm Des, 13, 2385, 10.2174/138161207781368710 Vin, 2003, Binding characteristics of SSR180575, a potent and selective peripheral benzodiazepine ligand, Biochem Biophys Res Commun, 310, 785, 10.1016/j.bbrc.2003.09.079 Ferzaz, 2002, SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair, J Pharmacol Exp Ther, 301, 1067, 10.1124/jpet.301.3.1067 Gibson, 2008, Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease, Ann N Y Acad Sci, 1147, 221, 10.1196/annals.1427.038 Apfel, 2000, Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial, JAMA, 284, 2215, 10.1001/jama.284.17.2215 Schifitto, 2001, Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy, Neurology, 57, 1313, 10.1212/WNL.57.7.1313 Wellmer, 2001, A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy, J Peripher Nerv Syst, 6, 204, 10.1046/j.1529-8027.2001.01019.x Evans, 2007, A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain, PLoS One, 2, e551, 10.1371/journal.pone.0000551 Reljanovic, 1999, Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II), Free Radic Res, 31, 171, 10.1080/10715769900300721 Ziegler, 2006, Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial, Diabetes Care, 29, 2365, 10.2337/dc06-1216